MoonLake Immunotherapeutics (MLTX) Q1 2026 Earnings
MLTX·Reported May 11, 2026·Before market open
Diluted EPS came in at $-0.98 (-55.6% YoY), missed the $-0.91 consensus by $0.07.
Diluted EPS
$-0.98missed by $0.07
Consensus: $-0.91
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about MoonLake Immunotherapeutics's Q1 2026 earnings report.
MoonLake Immunotherapeutics (MLTX) reported Q1 2026 earnings on May 11, 2026 before market open.
MoonLake Immunotherapeutics reported diluted EPS of $-0.98 for Q1 2026.
EPS missed the consensus estimate of $-0.91 by $0.07.
Compared to the same quarter a year prior, diluted EPS declined 55.6% from $-0.63.
You can read the 8-K earnings release (0001821586-26-000005) and the 10-Q periodic report (0001821586-26-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.